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Background/aim: This study was designed to determine the characteristic features of upper urinary system urothelial carcinomas
(UUSUCs) and to evaluate the clinicopathological parameters associated with prognosis.
Materials and methods: A total of 74 cases of UUSUC were included, from three different centers. Demographic data and
histopathological features such as tumor localization, concomitant tumor in the urinary system, distant metastasis with overall survival
and disease-free survival obtained from the hospital records were evaluated retrospectively. Histopathologic prognostic features such as
grade, perineural invasion, lymphovascular invasion, tumor necrosis, and surgical margin status were also evaluated.
Results: Seventy cases (94.6%) underwent open nephroureterectomy whereas 4 cases (5.4%) had laparoscopic nefroureterectomy.
Thirty-eight (51.4%) cases were located in the pelvis, 7 (9.5%) in the ureter, 29 (39.2%) both in the pelvis and ureter. Fifty-six (75.7%)
cases were alive; however, 18 (24.3%) patients were found to be dead. pTa, pT1, pT2, pT3, and pT4 tumors were reported in 16 (21.6%),
13 (17.6%), 4 (5.4%), 28 (37.8%), and 13 (17.6%) patients, respectively. Histopathologically, 17 cases (23%) were low-grade, 57 cases
(77%) were high-grade. Statistically significant correlation was observed between overall survival and lymph node metastasis, distant
metastasis, tumor necrosis, and differentiation by univariate analysis. Only distant metastasis was statistically associated with overall
survival by multivariate analysis. We found no significant relationship between disease-free survival and all parameters.
Conclusions: Differentiation and necrosis of tumor, lymph node involvement, and presence of distant metastasis is associated with the
overall survival of urothelial carcinoma of the upper urinary system.
Key words: Prognostic factors, upper tract urothelial carcinomas, upper urinary tract, urothelial carcinomas

1. Introduction
Urothelial carcinomas (UC) can arise in any part of the
urinary tract lined by urothelium; however, the majority of
cases are located in the lower tract (bladder, urethra) (1,2).
Upper urinary system urothelial carcinomas (UUSUC),
including renal pelvis and ureteral tumors, are known to
be rare tumors, which constitute approximately 5%–10%
of all UCs. The natural history and prognosis of UUSUC
differ from bladder cancer (3–6). Among UUSUC, 60%
of cases are invasive at diagnosis while only 15%–25% of
bladder tumors are invasive at initial diagnosis. Moreover,
the prognosis of UUSUC is poor and five year recurrencefree and overall survival (OS) rates are reported as 28%
and 23%, respectively (1,2,7–13).

There are many studies in the literature evaluating
the factors affecting the prognosis of the UC but the
data about the prognostic factors of UUSUC are limited
(1, 7, 9, 12-16). In this study, we evaluated the effect of
clinicopathological factors including age, sex, tumor grade,
tumor stage, tumor necrosis, lymphovascular invasion
(LVI), perineural invasion (PNI), lymph node metastasis
(LNM), and distant metastasis on OS of UUSUC.
2. Materials and methods
A total of 74 cases diagnosed with UUSUC from three
different centers between February 2000 and December
2017 were included in the study. In patients with suspicion
of UUSUC, diagnosis was obtained radiologically by using
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computed tomography urography which has the highest
diagnostic accuracy among all of the clinically available
imaging techniques. Radical nephroureterectomy with
bladder cuff excision was performed without compromising
oncological principles. Avoidance of entry into the urinary
tract during surgery was taken into consideration in order
to prevent tumor seeding in both open and laparoscopic
nephroureterectomy cases. Approach to distal ureter was
either performed with open or endoscopic techniques.
Lymph node dissection was performed in case of clinical
or radiological suspicion for metastasis. The demographic
and clinicopathological features such as age, sex, tumor
localization, distant metastasis, and concomitant tumor
development in the urinary system and OS were obtained
from urology records. Hematoxylin-eosin–stained slides
were revised and histological grade, stage, differentiation,
PNI, LVI, necrosis, LNM, and the status of the surgical
margins were noted. World Health Organization (WHO)
2016 classification of urinary tumors was used for tumor
grading and staging (17).
2.1. Statistical analysis
The correlation between OS and disease-free survival
(DFS) and age, tumor size, tumor grade, tumor stage,
tumor differentiation, concomitant UC, surgical margin,
PNI, LVI, LNM, necrosis, and distant organ metastasis
were investigated using Kaplan–Meier method, and log
rank analysis. Multivariate analyses of OS were performed
using the Cox regression method. P < 0.05 was considered
to be the level of statistical significance. The OS and DFS of
all patients during follow-up were assessed and statistical
analysis was performed with SPSS version 24 (IBM Corp.;
Armonk, NY, USA).
3. Results
Seventy cases (94.6%) underwent open nephroureterectomy
whereas four cases (5.4%) had laparoscopic
nefroureterectomy. Thirty-eight (51.4%) tumors were
located in the pelvis, 7 (9.5%) in the ureter, and 29 (39.2%)
both in the pelvis and ureter. Sixty (81.1%) patients were
male and 14 (18.9%) were female. The ages at the time of
diagnosis ranged from 40 to 84 years with a median age
of 63.8 years. The follow-up time of all patients was 43.5
months (±48.7) (min: 1 month-max: 204 months). Twentyseven cases (36.5%) were ≥70 years of age whereas 47
cases (63.5%) were <70. Fifty-six (75.7%) cases were alive;
however, 18 (24.3%) patients were found to be dead. The
mean tumor size was 5.4 cm (0.3–17 cm). pTa, pT1, pT2,
pT3, and pT4 tumors were reported in 16 (21.6%), 13
(17.6%), 4 (5.4%), 28 (37.8%), and 13 (17.6%) patients,
respectively. Histopathologically, 17 cases (23%) were lowgrade and 57 cases (77%) were high-grade (Table 1).
Twenty-two cases (29.7%) showed variant differentiation
(19 squamous, 2 sarcomatoid, 1 glandular differentiation).
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Necrosis, LVI, PNI, and LNM was observed in 29
(39.2%), 25 (33.8%), 9 (12.2%), and 10 (13.5%) cases,
respectively. Furthermore, 13 cases (17.6%) showed
positive surgical margin (Table 1).
According to the follow-up data, 6.3% of cases with
stage pTa, 23.1% of cases with stage pT1, 35.7% of cases
with stage pT3, and 30.8% of the cases with stage pT4 were
dead. All the cases with stage pT2 were alive. There was no
statistically significant correlation between stage, tumor
localization, positive surgical margin, and OS (P = 0.19, P
= 0.324, P = 0.28, respectively).
Two of 17 low-grade carcinomas (11.8%) and 16 of
57 high-grade carcinomas (28.1%) were dead and no
statistically significant correlation was found between
tumor grade and OS (P = 0.14).
Concomitant bladder tumor was detected in 31
cases (41.9%). The tumor was located in bladder and
contralateral kidney in one case (1.4%). However, the
association between prognosis and concomitant urothelial
cancer was not significant (P = 0.45).
In addition, no statistically significant correlation was
found between sex, age over or under 70, tumor size, PNI,
LVI, and OS (P = 0.11, P = 0.774, P = 0.21, P = 0.13, P
= 0.74, respectively). However, statistically significant
association was observed between OS and differentiation
(Figure 1), necrosis (Figure 2), LNM (Figure 3), and distant
metastasis (Figure 4) (P < 0.001, P < 0.001, P < 0.001, P =
0.042, respectively).
There was no significant correlation between
synchronous tumor in the bladder (p=0.45) and OS
as well as distant metastasis, differentiation, necrosis,
LNM, and LVI (P = 0.96, P = 0.43, P = 0.79, P = 0.64,
P = 0.92, respectively). Only distant metastasis was
statistically associated with OS by multivariate analysis (P
= 0.037). Table 2 demonstrates the multivariate analysis of
parameters affecting OS.
Six of 74 cases had recurrence and 2 of these 6 cases
were dead. We observed no significant relationship
between recurrence and OS (P = 0.57).
The pathological stages of these recurrent cases were
found as pTa (n=1), pT3 (n=4), and pT4 (n = 1). Five
cases were high-grade whereas one case was low-grade.
Two recurrent cases had LVI, concomitant bladder tumor
and metastasis. None of them showed PNI. One case had
tumor positive surgical margins.
We found no significant relationship between DFS
and age (over/under 70), stage, tumor grade, LVI, PNI,
surgical margin positivity, concomitant bladder tumor and
metastasis. (P = 0.711, P = 0.436, P = 0.549, P = 0.918, P =
0.393, P = 0.900, P = 0.207, P = 0.100, respectively).
Three of 45 cases without necrosis had recurrence in
addition to three cases with necrosis. Three of 52 cases
without any additional differentiation had recurrence.
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Table 1. Univariate analysis of demographic, clinical, and pathological characteristics for overall survival.
Clinicopathologic factors

Category

n (%)

Median age in years (range)

63.8 (min 40-max 84) (SD ± 8.9)

74

Age ≥ 70

27 (36.5)

Age <70

47 (63.5)

Tumor size

5.4 cm (min 0.3–max 17 cm)

Sex

Male

60 (81.1)

Female

14 (18.9)

Live

56 (75.7)

Ex

18 (24.3)

Open nefroureterectomy

70 (94.6)

Laparoscopic nefroureterectomy

4 (5.4)

Renal pelvis

38 (51.4)

Ureter

7 (9.5)

Survival
Initial surgery
Tumor location

Pathological T stage

Tumor grade
Differentiation

Lymph node metastasis
Lymphovascular invasion
Perineural invasion
Tumor necrosis
Surgical margins
Synchronous tumor

P-values
0.77
0.21

Renal pelvis and ureter

29 (39.2)

pTa

16 (21.6)

pT1

13 (17.6)

pT2

4 (5.4)

pT3

28 (37.8)

pT4

13 (17.6)

High

57 (77)

Low

17 (23)

Absence

52 (70.3)

Presence

22 (29.8)

Squamous

19 (25.7)

Sarcomatoid

2 (2.7)

Glandular

1 (1.4)

Absence

64 (86.5)

Presence

10 (13.5)

Absence

49 (66.2)

Presence

25 (33.8)

Absence

65 (87.8)

Presence

9 (12.2)

Absence

45 (60.8)

Presence

29 (39.2)

Negative

61 (82.4)

Positive

13 (17.6)

Absence

42(56.8)

Presence

32 (43.2)

Bladder

31 (41.9)

Bladder and contralateral kidney

1 (1.4)

Recurrent disease

Absence

68 (91.9)

Presence

6 (8.1)

Metastasis

Absence

58 (78.4)

Presence

16 (21.6)

0.11

0.324

0.19

0.14
<0.001

0.042
0.74
0.13
<0.001
0.28
0.45

0.57
<0.001
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Figure 1. Kaplan–Meier curves of overall survival stratified according to the histological differentiation of tumors.

Figure 2. Kaplan–Meier curves of overall survival stratified according to tumor necrosis.
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Figure 3. Kaplan–Meier curves of overall survival stratified according to lymph node metastasis. (LNM)

Figure 4. Kaplan–Meier curves of overall survival stratified according to distant metastasis.
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Table 2. Multivariate analysis of parameters predicting overall survival.
Levels

Hazard ratio

95% Cl
Lower bound

95% Cl
Upper bound

P-value

Tumor necrosis

Negative
Positive

5.483

0.895

33.583

0.066

Tumor differentiation

Negative
Positive

1.825

0.627

5.314

0.270

Lymph node metastasis

Negative
Positive

1.100

0.330

3.666

0.877

Metastasis

Negative
Positive

4.200

1.087

16.227

0.037

Three tumors with additional differentiation had recurrent
disease. None of the cases with recurrent disease had
lymph node metastasis. Four cases with no metastasis
and 2 cases with metastasis had recurrent disease. No
significant relationship was observed between DFS and
necrosis, differentiation and lymph node involvement (P
= 0.254, P = 0.103, P = 0.458, respectively).
4. Discussion
UUSUC is rare but a potentially lethal disease (7). Upper
urinary system tumors are generally multifocal affecting
all urinary system lined by urothelium (1,9). The mean
age of patients is reported as 65 years and the disease is
more common in men (8). Various studies focused on the
effect of clinical and pathologic parameters on UUSUC
outcomes (1,5,7,10,12,18–24). Several studies reported
tumor stage and grade as prognostic predictors in UUSUC
(1,5,7,10,18–24).
In two different studies of Kikucki et al. and Bolenz et
al., LVI was reported as an independent prognostic factor
of DFS in UUSUCs (6,25). In our study, LVI was observed
in 25 (33.8%) of 70 patients. There was no statistically
significant correlation between LVI and OS. The presence
of LVI should be stated in pathology reports in order to
follow up the patients. (6).
Green et al. reported that the prognosis of bladder
urothelial carcinoma is worse in women (10). Two
multiinstitutional analyses performed by Fernandez et al.
and Shariat et al. did not show any difference in pathologic
characteristics and outcomes between sexes in UUSUC
(1). Emamekhoo et al. reported that sex had no significant
effect on OS and DFS of 454 cases (5). Most of our cases
were men (n = 60) and no significant correlation was
observed between sex and OS.
The studies about tumor localization and prognosis
reported that ureteral tumors have a worse prognosis
than renal pelvic tumors (1,5,7,18). The reason of this
correlation is controversial while stage and treatment
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options may change (10). The protective effect of the renal
parenchyma is thought to be associated with this finding.
Also, the presence of a thin layer of adventitia surrounding
the ureter, which contains an extensive plexus of blood and
lymphatic vessels makes the invasion of tumor easier (21).
However, several studies did not confirm the independent
prognostic impact of tumor location on survival and
showed the same recurrence-free survival and cancerspecific survival rates for renal pelvis and ureteral tumors
(1,5). Similarly, we did not find a significant relation
between OS and tumor localization. Nevertheless, this
may be due to the unequal distribution of the cases for
tumor localization.
Histopathologically, UUSUCs are generally high-grade
tumors (9). Pathological tumor stage and histological
grade are accepted as main indicators for prognosis similar
to other malignant tumors (7,9,12,14,19–23). Most of the
cases were high-grade in our study. Sixteen of 57 highgrade carcinomas were dead while only 2 of 17 low-grade
carcinomas were found to be dead.
There was a correlation between grade or stage and OS;
however, it was not statistically significant and this may be
explained by the distribution numbers among the groups
(P = 0.14, P = 0.19).
The presence of tumor necrosis is an indicator of
aggressiveness in almost all malignancies (1,9,12).
However, recent studies reported controversial results
about the prognostic role of tumor necrosis in UUSUC
(1). In the study of Zhang et al., tumor necrosis was
found in 48 of 100 cases and was related to pathological
stage, higher tumor grade, LNM, and LVI (12). Seitz et al.
detected tumor necrosis in 165 of 754 cases (21.9%) from 9
different centers and showed that the prevalence of tumor
necrosis increased as the pathological stage increased.
Also, they reported that tumor necrosis was related to
higher grade, LNM, LVI, sessile tumoral architecture and
concomitant carcinoma in situ among UUSUC. However,
tumor necrosis was not an independent predictor of clinical
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outcome (24). In our study, necrosis showed significant
relation in univariate analysis; however, this relation was
not proven by multivariate analysis (P < 0.001, P = 0.66,
respectively). Larger studies are needed to prove this
correlation.
Lymph node involvement is generally accepted as
an important prognostic factor (1). The lymph node
status remains unknown because no lymphadenectomy
procedures were done in many nephroureterectomy
operations (5). Our clinical approach is the excision of
lymph nodes when palpable lymph nodes were observed
during the operation or when preoperative radiological
studies reported a suspect of lymph node positivity.
However, there are many studies showing that LNM
is an independent prognostic factor of UUSUC (1,7,12).
The effect of lymph node dissection on survival is still
controversial in nephroureterectomy for UUSUCs (26,27).
In the metaanalysis of Guo et al., patients with LNM had
worse prognosis (3). On the other hand, in the same
study, it was reported that lymphadenectomy showed no
significant difference on survival and recurrence in pN0 or
pNx cases (3).
We observed a significant association between lymph
node involvement and OS in univariate analysis; however,
this correlation was not proven by multivariate analysis (P
= 0.042, P = 0.877).
In the literature, distant metastasis is related to
prognosis in UUSUC (12,28). We also found a significant
relation between distant metastasis and OS by univariate
and multivariate analysis (P < 0.001, P = 0.037).
Even though the prognostic role of squamous
differentiation is accepted in UUSUC, the clinical
importance is still controversial (7,13,16). Most of the
studies revealed that squamous differentiation was
related to higher tumor grade and advanced tumor
stage in univariate analysis (13). Makise et al. observed
that squamous differentiation was the most common
histological variant among 140 primary UUSUC and
related with poor prognosis in univariate analysis (13). Qin
et al. suggested that differentiation was a poor prognostic
factor especially in ureteral tumors (7). We observed that
squamous differentiation is the most common variant and
it showed a statistically significant correlation with OS but
this was not proven by multivariate analysis (P < 0.001, P =
0.27, respectively).

The history of a bladder tumor is reported as a poor
prognostic factor in UUSUC in the literature and such
cases must be under more stringent follow-up regimens or
being treated more aggressively (1,29,30). There are studies
suggesting the effect of synchronous or metachronous
bladder cancer on recurrence and survival among
UUSUC (7). Novara et al. also reported that the presence
of concomitant muscle invasive bladder cancer is a poor
prognostic factor (23). Bladder was the most common
localization of concomitant tumors (n = 8) in our study.
One case had tumor in both bladder and kidney. However,
the presence of concomitant bladder tumor had no effect
on prognosis.
It was reported that the presence of bladder cancer
before the diagnosis of UUSUC has no significant effect
on prognosis (31). We could not subgroup our cases
according to the occurrence time of the previous bladder
tumor.
There are some studies supporting that cisplatin-based
additional treatments after surgery prolongs survival in
UUSUCs (4). In another study, adjuvant chemotherapy
after surgery was found to be associated with longer
cancer specific and recurrence-free survival in patients
with pT3N0M0 UUSUCs (32). The metastatic cases in our
study group had chemotherapy.
This study has several limitations that need to be
considered in interpreting the findings. The first limitation
is the retrospective nature of the study. Additionally, the
number of patients and the follow-up period are not
enough to fully interpret the results. Finally, surgical
procedures were performed by different surgeons at
different institutions, explaining both the variability of
intraoperative management and extent of lymph node
dissection. Despite these limitations, this study showed
that squamous differentiation, lymph node metastasis,
distant organ metastasis, and tumor necrosis have
statistically significant correlation with OS by univariate
analysis in patients with UUSUC. Nevertheless, distant
metastasis was the only statistically significant prognostic
factor of OS observed in multivariate analysis.
Finally, well-designed and larger multiinstitutional
studies are still needed to provide stronger evidence and
to promote the use of these prognostic factors in the
management of the treatment.
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